IPO registrations (S-1, F-1) · Underwriters
Wainwright
- Deals
- 10 priced offerings as an underwriter, 5 as lead manager or representative; 5 initial public offerings
- Proceeds of those deals
- $149,799,627 ($38,734,593 as lead)
- Years
- 2014–2025
- Named in
- 22 prospectuses and registration statements in all, including offerings not yet priced or withdrawn
- Named as
- Wainwright; Wainwright & Co; Wainwright & Co., LLC
Deals by year
| Year | Deals | As lead | Proceeds of deals |
|---|---|---|---|
| 2025 | 1 | 1 | $2,897,097 |
| 2022 | 1 | 0 | $6,000,002 |
| 2021 | 2 | 1 | $110,100,000 |
| 2020 | 4 | 2 | $17,632,532 |
| 2018 | 1 | 0 | $1,170,000 |
| 2014 | 1 | 1 | $11,999,996 |
Deals 10
| Priced | Company | Role | Price | Range | Shares | Proceeds | Listing | Kind | Syndicate | Prospectus |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-17 | Silexion Therapeutics Corp L3 | Lead | $1.35 | 2,145,998 | $2,897,097 | Nasdaq SLXN | IPO | 1 | 424B4 ↗ | |
| 2022-03-29 | Locafy Ltd C3 | Syndicate | $4.12 | 1,454,546 | $6,000,002 | Nasdaq LCFY | IPO | 3 | 424B4 ↗ | |
| 2021-03-09 | Gold Royalty Corp. A1 | Syndicate | $5.00 | 18,000,000 | $90,000,000 | NYSE American GROY | IPO | 8 | 424B4 ↗ | |
| 2021-02-11 | Biophytis SA | Lead | $16.75 | 1,200,000 | $20,100,000 | Nasdaq BPTS | IPO | 1 | 424B4 ↗ | |
| 2020-07-27 | MARA Holdings, Inc. FL | Syndicate | $0.90 | 6,666,667 | $6,000,000 | Nasdaq MARA | Offering | 3 | 424B4 ↗ | |
| 2020-07-06 | COSCIENS Biopharma Inc. A6 | Syndicate | $0.45 | 17,544,516 | $7,895,032 | TSX AEZS | Offering | 3 | 424B4 ↗ | |
| 2020-05-28 | GENETIC TECHNOLOGIES LTD C3 | Lead | $2.00 | 500,000 | $1,000,000 | Nasdaq GENE | Offering | 2 | 424B4 ↗ | |
| 2020-02-12 | Can-Fite BioPharma Ltd. L3 | Lead | $1.50 | 1,825,000 | $2,737,500 | NYSE American CANF | Offering | 2 | 424B4 ↗ | |
| 2018-11-27 | Ability Inc. L3 | Syndicate | $3.25 | 360,000 | $1,170,000 | Nasdaq ABIL | IPO | 3 | 424B4 ↗ | |
| 2014-02-13 | Oncotelic Therapeutics, Inc. CA | Lead | $2.05 | 5,853,657 | $11,999,996 | Nasdaq OXGN | Offering | 2 | 424B4 ↗ |
“Offering” is a priced registered offering that the cover page does not describe as an initial public offering: a follow-on, a resale, or a small company’s best-efforts deal.
Registrations in progress or never priced 3
| Filed | Company | Role | Range | Shares | Listing | Status | Document |
|---|---|---|---|---|---|---|---|
| 2022-08-17 | Baudax Bio, Inc. | Lead | 13,157,894 | Nasdaq BXRX | Priced 2022-08-31 (terms not read) | S-1/A ↗ | |
| 2022-02-28 | MPHASE TECHNOLOGIES, INC. | Syndicate | - | Nasdaq XDSL | Withdrawn 2003-04-25 | S-1 ↗ | |
| 2022-02-07 | BLUE BIOFUELS, INC. | Syndicate | - | OTC BIOF | Withdrawn 2022-05-02 | S-1 ↗ |
Works alongside
| Firm | Deals together | Of which that firm led |
|---|---|---|
| H.C. Wainwright | 8 | 5 |
| of Contents | 4 | 0 |
| BMO Capital Markets | 1 | 1 |
| Delivery of the | 1 | 0 |
| Raymond James | 1 | 0 |
| Roth Capital Partners | 1 | 0 |
| Scotiabank | 1 | 0 |
| TD Securities | 1 | 0 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Offering terms are read from the cover pages of the registrant's final prospectus (424B4, 424B1) and its latest registration statement before pricing: the price range, the final price, shares offered, gross proceeds (the cover's total, else price times shares), exchange and ticker, and the underwriters named on the cover and in the underwriting table (loader/s1_terms.py). Underwriter names are normalised, so Goldman, Sachs & Co. of 1999 and Goldman Sachs & Co. LLC of 2024 are one firm.